You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Characteristics of patients with brainstem metastases

From: Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases

Characteristic Value
Patients (F/M), n 36, (17/19)
Lesions, n 38
Median age (range), y 62 (28-89)
Primary Malignancy, n (%)  
Lung  14 (39%)
Breast  7 (19%)
Colon  4 (11%)
Other  11 (31%)
Symptoms, n (%)  25 (39%)
Headache  8 (22%)
Weakness  6 (17%)
Ataxia  7 (19%)
Visual Changes  6 (17%)
Median KPS score (range)  80 (60-90)
Median GPA score (range)  1.5 (0-3.5)
RPA class, n (%)  
I  4 (11%)
II  30 (83%)
III  2 (6%)
Number of intracranial metastases at time of SRS, n (%)  
1  9 (24%)
2 to 4  23 (61%)
>4  6 (16%)
Median interval between primary diagnosis and SRS (range), mo  16 (1-190)
Median tumor volume (cc), range  0.94 (0.01-4.2)
Location of treated brainstem metastasis, n (%)  
Midbrain  11 (29%)
Pons  25 (66%)
Medulla  2 (5%)
WBRT for brain metastases before SRS, n (%)  18 (47%)
Median SRS dose (range), Gy  17 (12-24)
Treatment Fractions, n (%)  
1  20 (56%)
2  2 (6%)
3  13 (36%)
5  1 (3%)
Treatment Modality, n (%)  
Cyberknife  34 (89%)
Trilogy  4 (11%)